PMID- 20614846
OWN - NLM
STAT- MEDLINE
DCOM- 20100730
LR  - 20211020
IS  - 0161-8105 (Print)
IS  - 1550-9109 (Electronic)
IS  - 0161-8105 (Linking)
VI  - 33
IP  - 7
DP  - 2010 Jul
TI  - Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with 
      recent onset of cataplexy.
PG  - 869-74
AB  - STUDY OBJECTIVE: Recent studies have found increased autoantibodies against 
      Tribbles homolog 2 (anti-TRIB2) and anti-streptolysin O (ASO) in narcolepsy. In 
      this study, we replicated this finding with a primary focus on recent onset 
      cases. PARTICIPANTS AND METHODS: Participants included (1) 90 cases with 
      cataplexy, (2) 57 cases without cataplexy, and (3) 156 age-sex matched controls, 
      including 73 human leukocyte antigen (HLA)-DQB1*0602 allele carriers. A 
      radioligand binding assay was used to detect anti-TRIB2 antibodies. RESULTS: 
      Anti-TRIB2 antibodies were prevalent in HLA-DQB1*0602 positive cases with 
      cataplexy (25.0% of 76) and rare in cases without cataplexy (3.5% of 57, OR = 
      9.2, 95% CI = 2.5 - 33.5, P = 6.0 x 10(-4)) or controls (4.5% of 156, OR = 7.1, 
      95% CI = 3.1 - 16.2, P = 9.3 x 10(-6)). Anti-TRIB2 positivity in controls was not 
      associated with DQB1*0602. In DQB1*0602 narcolepsy-cataplexy cases, the presence 
      of anti-TRIB2 was associated with short disease duration (2.3 years from 
      cataplexy onset), with 41.0% positive in this group (OR = 7.4 versus cases with 
      onset > 2.3 years, 95% CI = 1.9- 28.5, P = 9.0 x 10(-4)). Anti-TRIB2 positivity 
      in 39 DQB1*0602 positive recent onset cases was associated with increased ASO 
      antibody (> 200 IU) (OR = 6.2, 95% CI = 1.6 - 24.6, P = 0.01), but did not 
      correlate with age, gender, or body mass index. CONCLUSION: Anti-TRIB2 
      autoantibodies are strongly associated with narcolepsy close to cataplexy onset 
      (< or = 2.3 years). Anti-TRIB2 was rarely found in cases without cataplexy or 
      with distant onset.
FAU - Kawashima, Minae
AU  - Kawashima M
AD  - Center for Narcolepsy, Stanford University School of Medicine, 701-B Welch Road, 
      Palo Alto, CA 94304, USA. mina-e@umin.ac.jp
FAU - Lin, Ling
AU  - Lin L
FAU - Tanaka, Susumu
AU  - Tanaka S
FAU - Jennum, Poul
AU  - Jennum P
FAU - Knudsen, Stine
AU  - Knudsen S
FAU - Nevsimalova, Sona
AU  - Nevsimalova S
FAU - Plazzi, Giuseppe
AU  - Plazzi G
FAU - Mignot, Emmanuel
AU  - Mignot E
LA  - eng
GR  - P50 NS023724/NS/NINDS NIH HHS/United States
GR  - NS-23724/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Sleep
JT  - Sleep
JID - 7809084
RN  - 0 (Autoantibodies)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinases)
RN  - EC 2.7.11.17 (TRIB2 protein, human)
SB  - IM
CIN - Sleep. 2010 Jul;33(7):857-8. PMID: 20614841
MH  - Adult
MH  - Autoantibodies/*immunology
MH  - Autoimmunity/*immunology
MH  - Calcium-Calmodulin-Dependent Protein Kinases
MH  - Cataplexy/*complications
MH  - Female
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/*immunology
MH  - Male
MH  - Narcolepsy/*immunology
MH  - Odds Ratio
MH  - Radioligand Assay/methods
PMC - PMC2894428
EDAT- 2010/07/10 06:00
MHDA- 2010/07/31 06:00
PMCR- 2011/01/01
CRDT- 2010/07/10 06:00
PHST- 2010/07/10 06:00 [entrez]
PHST- 2010/07/10 06:00 [pubmed]
PHST- 2010/07/31 06:00 [medline]
PHST- 2011/01/01 00:00 [pmc-release]
AID - 10.1093/sleep/33.7.869 [doi]
PST - ppublish
SO  - Sleep. 2010 Jul;33(7):869-74. doi: 10.1093/sleep/33.7.869.